This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Multiple myeloma
  • /
  • The potential of ixazomib, a second-generation pro...
Journal

The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma.

Read time: 1 mins
Published:1st Jul 2017
Author: Brayer J, Baz R.
Availability: Free full text
Ref.:Ther Adv Hematol. 2017;8(7):209-220.
DOI:10.1177/2040620717710171

The therapeutic armamentarium for multiple myeloma has recently benefited from the addition of several new agents (including second-generation proteasome inhibitors, monoclonal antibodies and histone deacetylase inhibitors). This review will focus on ixazomib, an orally bioavailable second-generation proteasome inhibitor. Specifically, we will review the preclinical data, clinical trial experience, potential indications as well as unanswered questions pertaining to this new agent in multiple myeloma.

 

Read abstract on library site

Access full article